Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Rotarix vaccine shows strong protection against severe rotavirus in kids

NCT ID NCT01871038

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how effective the Rotarix vaccine is at preventing severe rotavirus infections in children under 6 years old. Researchers enrolled 362 children with acute gastroenteritis at two U.S. hospitals, comparing those who tested positive for rotavirus (cases) with those who tested negative (controls). By analyzing vaccination records, they estimated the vaccine's effectiveness in real-world conditions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Rotarix (RV1) vaccine
What this could lead to
If successful, this study confirms that Rotarix effectively prevents severe rotavirus infections in young children, supporting continued vaccine use.
What could go wrong
This is an observational case-control study, not a randomized trial, so results may be influenced by unmeasured factors. Vaccine effectiveness can vary by region and circulating strains.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

362 people

The number who actually took part.

Start date

Jul 2009

Finished

Jun 2012

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Children who are an inpatient or a patient of the Emergency Department with symptoms of acute gastroenteritis.

Ages

Up to 5 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * the child is \< 6 years of age * for the vaccine effectiveness analysis using the Minimum Age Model, the child was included if born on or after 8/10/2008 at MUSC and on or after 12/1/2008 at CCHMC. * for the vaccine effectiveness analysis using the Maximum Age Model, the child was included if \>=8 months of age. * the child is being evaluated at Cincinnati Children's Hospital Medical Center (CCHMC) or the Medical University of South Carolina (MUSC) as an inpatient, short-stay visit or in the emergency department * the child has acute gastroenteritis defined as * diarrhea (\>3 loose stools in a 24 hour period) OR * -vomiting (\>1 episodes in a 24 hour period) * the child's illness is of \<10 days duration * written consent is obtained from the child's parent or legal guardian Exclusion Criteria: * the child is \>6 year of age * the child had onset of fever or gastroenteritis symptoms \> 10 days prior to admission * the child has a non-infectious or other identifiable cause of their symptoms, such as head trauma, pyelonephritis, pyloric stenosis, or prolonged coughing * the child is immunocompromised * there is no parent or guardian available * the parent/guardian is non-English speaking * previously enrolled for the same episode of gastroenteritis * for the vaccine effectiveness analysis using the Minimum Age Model, the child was excluded if born prior to 8/10/2008 at MUSC and prior to 12/1/2008 at CCHMC. * for the vaccine effectiveness analysis using the Maximum Age Model, the child was excluded if \<8 months of age.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute gastroenteritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Medical University of South Carolina

    Charleston, South Carolina, 29425, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.